pm 1635

SAS:dsli, 1/22/07 899-73077-04 639338 737

PATENT Attorney Reference Number 899-73077-04

SYÍN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Nelson et al.

Application No. 10/564,369

Filed: August 23, 2006 Confirmation No. 7108

For: METHODS OF TREATMENT AND

DIAGNOSIS USING MODULATORS OF VIRUS-INDUCED CELLULAR GENE

SEQUENCES

Examiner: Not yet assigned.

Art Unit: 1635

Attorney Reference No. 899-73077-04

COMMISSIONER FOR PATENTS P.O. BOX 1450 ALEXANDRIA, VA 22313-1450

CERTIFICATE OF MAILING

I hereby certify that this paper and the documents referred to as being attached or enclosed herewith are being deposited with the United States Postal Service as First Class Mail in an envelope addressed to: COMMISSIONER FOR PATENTS, P.O. BOX 1450, ALEXANDRIA, VA 22313-1450 on the date shown below.

Attorney or Agent for Applicant(s)___

Date Mailed January 22,

TRANSMITTAL LETTER

Enclosed for filing in the application referenced above are the following:

- Supplemental Information Disclosure Statement
- Form 1449 and 3 references cited thereon
- Copy of International Search Report from PCT Application NO. PCT/US2004/011988
- The Director is hereby authorized to charge any additional fees that may be required, or credit over-payment, to Deposit Account No. 02-4550. A copy of this sheet is enclosed.
- Please return the enclosed postcard to confirm that the items listed above have been received.

Respectfully submitted,

KLARQUIST SPARKMAN, LLP

One World Trade Center, Suite 1600

121 S.W. Salmon Street Portland, Oregon 97204 Telephone: (503) 595-5300

Facsimile: (503) 595-5301

cc: Docketing

By

Susan Alpert Siegel, Ph.D. Registration No. 43,121



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Nelson et al.

Application No. 10/564,369

Filed: August 23, 2006 Confirmation No. 7108

For: METHODS OF TREATMENT AND

DIAGNOSIS USING MODULATORS OF VIRUS-INDUCED CELLULAR GENE

SEQUENCES

Examiner: Not yet assigned.

Art Unit: 1635

Attorney Reference No. 899-73077-04

Date Mail

Date Mailed January 22, 2007

date shown below.

Attorney or Agent

for Applicant(s)

CERTIFICATE OF MAILING

I hereby certify that this paper and the documents referred to as being attached or enclosed herewith are being deposited

with the United States Postal Service as First Class Mail in an envelope addressed to: COMMISSIONER FOR PATENTS,

P.O. BOX 1450, ALEXANDRIA, VA 22313-1450 on the

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT PURSUANT TO 37 C.F.R. § 1.97(b)(3)

COMMISSIONER FOR PATENTS P.O. BOX 1450 ALEXANDRIA, VA 22313-1450

Listed on the accompanying form PTO-1449 and enclosed herewith are three English-language documents. Applicants respectfully request that these documents be listed as references cited on the issued patent. A copy of the International Search Report of parent application no. PCT/US2004/011988 is also enclosed.

Applicants are filing this Information Disclosure Statement ("IDS") before the mailing date of a first Office action on the merits. As a result, no fee should be required to file this IDS. However, if the Patent Office determines that a fee is required for Applicants to file this IDS, deposit account authority is provided on the accompanying transmittal letter.

The filing of this IDS shall not be construed to be an admission that the information cited in the statement is, or is considered to be, prior art or otherwise material to patentability as defined in 37 C.F.R. §1.56.

One World Trade Center, Suite 1600 121 S.W. Salmon Street

Portland, Oregon 97204 Telephone: (503) 595-5300

Facsimile: (503) 595-5301

Respectfully submitted,

KLARQUIST SPARKMAN, LLP

By .

Susan Alpert Siegel, Pk.D. Registration No. 43,121

INFORMATION DISCLOSURE STATEMENT
BY APPLICANT

Attorney Docket Number	899-73077-04
Application Number	10/564,369
Filing Date	August 23, 2006
First Named Inventor	Nelson
Art Unit	1635
Examiner Name	Not yet assigned

		Examiner Name Not yet assigned		
Examiner's Initials*	Cite No. (optional)	OTHER DOCUMENTS		
		Branch A., "A good antisense molecule is hard to find," TIBS 23:45-20, February 1998		
		Fleming, et al., "Regulation of vascular endothelial growth factor expression in human colon carcinoma cells by activity of src kinase," <i>Surgery</i> 122:50-507, 1997		
		Jen and Gewirtz, "Suppression of Gene Expression by Targeted Disruption of Messenger RNA: Available Options and Current Strategies," Stem Cells 18:307-319, 2000		

EXAMINER	DATE
SIGNATURE:	CONSIDERED:

^{*} Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.